Loading...
Loading...
75A50126R00002
Response Deadline
Jul 30, 2026, 9:00 PM(EDT)43 days
Eligibility
Contract Type
Solicitation
BARDA seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.
Erin Greninger, Contracting Officer
Greg Smith
DEPARTMENT OF HEALTH AND HUMAN SERVICES
OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
BARDA - ASPR / DAAPPO / BARDA DCMA
BARDA - ASPR / DAAPPO / BARDA DCMA
O’NEILL HOUSE OFFICE BUILDING
WASHINGTON, DC, 20515
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
PSC
COMMUNITY AND REGIONAL DEVELOPMENT R&D SERVICES; COMMUNITY DEVELOPMENT; APPLIED RESEARCH
Set-Aside
No Set aside used